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Introduction
============

Although the incidence of opioid-induced respiratory depression in the post-operative setting is low, it is of major concern to clinicians because of the potential for fatal consequences when clinical monitoring is inadequate. Of additional concern is the large increase in opioid-related deaths over the past decade due to respiratory depression, particularly in overdose and in individuals consuming other central nervous system depressants such as sedatives and alcohol ^[@ref-1]^. The opioids may have been prescribed for the management of chronic pain or they may have been obtained through diversion of prescribed opioids or by illicit means. Opioid-related deaths due to respiratory depression have risen in parallel with the marked increase in opioid consumption, particularly in the United States of America, over this period ^[@ref-2]^. Disturbingly, chronic opioid use accounts for an estimated 24% of central sleep apnea that can go unnoticed and be fatal without appropriate intervention ^[@ref-3]^. Apart from strategies aimed at risk mitigation by reducing clinical opioid administration, drug discovery programs have been aimed at discovering a new generation of opioids that retain potent analgesic activity but with less respiratory depression ^[@ref-4]--\ [@ref-6]^. Another strategy, which is the subject of this review, is to identify respiratory stimulant molecules for potential co-administration with an opioid analgesic to counter opioid-related respiratory depression whilst sparing opioid analgesia.

Recent advances in countering opioid-induced respiratory depression
===================================================================

Classes of molecules showing promising preclinical and/or clinical results to date include ampakines, 5-hydroxytryptamine (5-HT) receptor agonists, phosphodiesterase-4 inhibitors, D ~1~-dopamine receptor agonists, nicotinic acetylcholine receptor agonists, acetylcholine esterase inhibitors, bradykinin receptor antagonists, N-methyl-D-aspartate (NMDA) receptor antagonists, protein kinase A inhibitors, G-protein-gated inwardly rectifying potassium channel (GIRK) blockers, α ~2~-adrenoceptor antagonists, and chemoreceptor stimulants (see summary in [Table 1](#T1){ref-type="table"}). For a more detailed discussion, see the excellent review by Dahan and colleagues ^[@ref-2]^. Herein, we have focused only on the most recent research on these experimental respiratory stimulants.

###### Summary of non-opioid molecules assessed for their ability to counter opioid-induced respiratory depression.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Pharmacological\        Molecule                 Dose, route                  Receptor/target\               Co-administered opioid\                Species (strain/sex)                       Effect                                  Reference
  class                                                                         interaction                    (dose)                                                                                                                    
  ----------------------- ------------------------ ---------------------------- ------------------------------ -------------------------------------- ------------------------------------------ --------------------------------------- -----------
  *Ampakines*             CX717                    1,500 mg, oral               AMPA                           Alfentanil (100 ng/ml\                 Human (males)                              ↑ Respiratory frequency; ↑\             [@ref-18]
                                                                                                               plasma concentration)                                                             hemoglobin oxygenation; less\           
                                                                                                                                                                                                 decrease of slope of the linear\        
                                                                                                                                                                                                 relationship between expiratory\        
                                                                                                                                                                                                 volume/minute and CO ~2~\               
                                                                                                                                                                                                 concentration in expired air (in\       
                                                                                                                                                                                                 hypercapnic challenge)                  

  15 mg/kg, i.v.          AMPA                     Fentanyl (60 µg/kg, i.v.)    Rat (SD)                       ↑ Respiratory frequency; ↑\            [@ref-19]                                                                          
                                                                                                               oxygen saturation                                                                                                         

  15 mg/kg, i.v.          AMPA                     Fentanyl (60 µg/kg, i.v.)    Rat (SD)                       ↑ Respiratory frequency and\           [@ref-20]                                                                          
                                                                                                               amplitude                                                                                                                 

  CX546                   16 mg/kg, i.p.           AMPA                         Fentanyl                       Rat (SD)                               ↑ Respiratory frequency; ↑ burst\          [@ref-21]                               
                                                                                                                                                      amplitude; no effect on behavior\                                                  
                                                                                                                                                      or arousal state                                                                   

  15 mg/kg, i.p.          AMPA                     Morphine (10 mg/kg, i.p.)    Rat (SD)                       ↑ Respiratory rate; ↑ tidal volume;\   [@ref-22]                                                                          
                                                                                                               ↑ minute ventilation                                                                                                      

  CX1942                                           AMPA                         Etorphine (0.1 mg/kg, i.v.)    Boer goat ( *Capra*\                   ↑ Tidal volume; ↑ ventilation; ↑\          [@ref-12]                               
                                                                                                               *hircus*)                              PaO ~2~; ↑ SaO ~2~; ↓ PaCO ~2~                                                     

  LCX001                  10 mg/kg, i.v.           AMPA                         Fentanyl (120 μg/kg, s.c.)     Rat (SD)                               ↑ Respiratory rate; ↑ minute\              [@ref-9]                                
                                                                                                                                                      ventilation                                                                        

  XD-8-17C                1--30 mg/kg, i.v.        AMPA                         TH-030418 (acute death --\     Mouse (KM), rat (SD)                   Protection against acute\                  [@ref-23]                               
                                                                                15 mg/kg, s.c.; respiration\                                          opioid-induced death; reversal\                                                    
                                                                                -- 20 µg/kg, i.v.)                                                    of depression of respiratory\                                                      
                                                                                                                                                      parameters (respiratory\                                                           
                                                                                                                                                      frequency, minute ventilation,\                                                    
                                                                                                                                                      pO ~2~, sO ~2~) to normal; no effect on\                                           
                                                                                                                                                      morphine antinociception                                                           

  Tianeptine              2 and 10 mg/kg, i.p.     AMPA                         Morphine (10 mg/kg, i.p.)      Rat (SD)                               ↑ Respiratory rate; ↑ tidal volume;\       [@ref-22]                               
                                                                                                                                                      ↑ minute ventilation                                                               

  *5-HT agonists*         Buspirone                50 µg/kg, i.v.               5-HT ~1A~                      Morphine (21.3 ± 2.1\                  Rat (SD)                                   Counteracted morphine-induced\          [@ref-24]
                                                                                                               mg/kg, i.v.)                                                                      apnea                                   

  Repinotan               10 and 20 μg/kg, i.v.    5-HT ~1A~                    Remifentanil (2.5 µg/kg,\      Rat (SD)                               ↑ Minute ventilation                       [@ref-25]                               
                                                                                i.v.)                                                                                                                                                    

  Befiradol               0.2 mg/kg                5-HT ~1A~                    Fentanyl (60 μg/kg, i.v.)      Rat (SD)                               ↑ Respiratory frequency; ↑ tidal\          [@ref-26]                               
                                                                                                                                                      volume; ↑ minute ventilation                                                       

  BIMU8                   1--2 mg/kg, systemic     5-HT ~4A~                    Fentanyl (10--15 μg/kg,\       Rat (SD)                               ↑ Respiratory minute volume                [@ref-27]                               
                                                                                systemic)                                                                                                                                                

  8-OH-DPAT               0.5 mg/kg, i.v.          5-HT ~1A~ and 5-HT ~7~       Etorphine hydrochloride\       Boer goat ( *Capra*\                   ↓ Time to recumbency; ↑\                   [@ref-28]                               
                                                                                (0.06 mg/kg, i.m.)             *hircus*)                              respiratory rate; ↑ PaO ~2~; ↓ PaCO ~2~                                            

  8-OH-DPAT               10 or 100 µg/kg          5-HT ~1A~                    Morphine (21.3 ± 2.1\          Rat (SD)                               Counteracted morphine-induced\             [@ref-24]                               
                                                                                mg/kg, i.v.)                                                          apnea                                                                              

  Zacopride               0.5 mg/kg, i.v.          5-HT ~4~                     Etorphine hydrochloride\       Boer goat ( *Capra*\                   ↓ Time to recumbency; ↑\                   [@ref-28]                               
                                                                                (0.06 mg/kg, i.m.)             *hircus*)                              respiratory rate; ↑ PaO ~2~; ↓ PaCO ~2~                                            

  *Phosphodiesterase-*\   Caffeine                 20 mg/kg, i.v.               PDE4                           Morphine (0.4 mg/kg/\                  Rat                                        ↑ Inspiratory time; ↓ respiratory\      [@ref-29]
  *4 inhibitors*                                                                                               minute, i.v.)                                                                     rate                                    

  3 and 10 mg/kg, i.v.    PDE4                     Morphine (1.0 mg/kg, i.v.)   Rat (WH)                       Recovered prolongation and\            [@ref-30]                                                                          
                                                                                                               flattening effect on inspiratory\                                                                                         
                                                                                                               discharge in the phrenic nerve by\                                                                                        
                                                                                                               morphine                                                                                                                  

  Rolipram                0.1 and 0.3 mg/kg,\      PDE4                         Morphine (1.0 mg/kg, i.v.)     Rat (WH)                               Recovered prolongation and\                [@ref-30]                               
                          i.v.                                                                                                                        flattening effect on inspiratory\                                                  
                                                                                                                                                      discharge in the phrenic nerve by\                                                 
                                                                                                                                                      morphine                                                                           

  *D1-dopamine*\          6-Chloro-APB             0.5--3 mg/kg                 D ~1~                          Fentanyl citrate (15--35\              Cat                                        Reversal of fentanyl-induced\           [@ref-31]
  *receptor agonists*                                                                                          µg/kg)                                                                            abolition of phrenic and vagus\         
                                                                                                                                                                                                 nerve respiratory discharges and\       
                                                                                                                                                                                                 firing of bulbar post-inspiratory\      
                                                                                                                                                                                                 neurons                                 

  Dihydrexidine           0.5--2.0 mg/kg           D ~1~                        Fentanyl citrate (15--35\      Cat                                    Reversal of fentanyl-induced\              [@ref-31]                               
                                                                                µg/kg)                                                                abolition of phrenic and vagus\                                                    
                                                                                                                                                      nerve respiratory discharges and\                                                  
                                                                                                                                                      firing of bulbar post-inspiratory\                                                 
                                                                                                                                                      neurons                                                                            

  SKF-38393               1.5--3 mg/kg             D ~1~                        Fentanyl citrate (15--35\      Cat                                    Reversal of fentanyl-induced\              [@ref-31]                               
                                                                                µg/kg)                                                                abolition of phrenic and vagus\                                                    
                                                                                                                                                      nerve respiratory discharges and\                                                  
                                                                                                                                                      firing of bulbar post-inspiratory\                                                 
                                                                                                                                                      neurons                                                                            

  *BK-channel blocker*    GAL021                   Stepped drug\                Carotid body                   Alfentanil (stepped drug\              Human --healthy                            ↑ respiratory rate; ↑ tidal volume      [@ref-32]
                                                   infusion                                                    infusion)                                                                                                                 

                          GAL021                   (0.6, 1.5, and 6.0\          Carotid body                   Morphine (10 mg/kg, i.v.)              Rat (SD)                                   ↑ Minute volume; ↑ tidal volume;\       [@ref-33]
                                                   mg/ml; 0.04, 0.1, and\                                                                                                                        ↑ PaO ~2~; ↑ pH; ↓ PaCO ~2~             
                                                   0.4 mg/kg/minute)                                                                                                                                                                     

                                                   5-minute load of 0.2\        Carotid body                   Morphine (3--4 mg/kg, i.v.)            Cynomolgus monkeys                         ↓ End-tidal carbon dioxide (ET ~CO2~)   [@ref-33]
                                                   or 0.1 mg/kg/minute\                                                                                                                                                                  
                                                   i.v. + maintenance\                                                                                                                                                                   
                                                   infusion 0.1 or 0.05\                                                                                                                                                                 
                                                   mg/kg/minute                                                                                                                                                                          

  Chemoreceptor\          Almitrine                0.03, 0.1 mg/kg/\            Peripheral\                    Morphine (10 mg/kg, i.v.)              Rat (SD)                                   *Normoxia*: ↑ respiratory\              [@ref-34]
  stimulant                                        minute, i.v.                 chemoreceptors                                                                                                   frequency; ↑ tidal volume;\             
                                                                                                                                                                                                 *Hypoxia*: ↓ respiratory frequency;\    
                                                                                                                                                                                                 ↑ tidal volume (0.03 mg/kg/\            
                                                                                                                                                                                                 minute); ↓ tidal\                       
                                                                                                                                                                                                 volume (0.1 mg/\                        
                                                                                                                                                                                                 kg/minute)                              

  Doxapram                1 mg/kg, i.v.            Carotid body                 Etorphine (0.1 mg/kg, i.v.)    Boer goat ( *Capra*\                   ↑ Respiratory frequency; ↑\                [@ref-12]                               
                                                                                                               *hircus*)                              ventilation; ↑ PaO ~2~; ↑ SaO ~2~; ↓\                                              
                                                                                                                                                      PaCO ~2~                                                                           

  Nicotinic\              Nicotine                 0.6 mg/kg, s.c.              α4β2                           Fentanyl (35 µg/kg, s.c.)              Rat (SD)                                   ↑ respiratory frequency; ↑ tidal\       [@ref-10]
  acetylcholine\                                                                                                                                                                                 volume; ↑ minute ventilation;           
  receptor agonist                                                                                                                                                                                                                       

  A85380                  0.03 to 0.06 mg/kg,\     α4β2                         Fentanyl (35 µg/kg, s.c.)      Rat (SD)                               ↑ respiratory frequency; ↑ tidal\          [@ref-10]                               
                          s.c.                                                                                                                        volume; ↑ minute ventilation                                                       

  N-methyl-D-\            Esketamine               0.57 mg/kg, i.v.,\           NMDA                           Remifentanil (0.1--0.5\                Human -- healthy                           Stimulatory effect on ventilatory\      [@ref-35]
  aspartate\                                       cumulative                                                  ng/ml, i.v.)                                                                      CO ~2~ sensitivity                      
  receptor antagonist                                                                                                                                                                                                                    

  Protein kinase A\       H89                      50 µg, i.c.v.                --                             Fentanyl (60 µg/kg)                    Rat (SD)                                   ↑ respiratory frequency; ↑\             [@ref-36]
  (PKA) inhibitor                                                                                                                                                                                inspiratory time; ↓ expiratory time     

  GIRK channel\           Tertiapin-Q              0.5--2 µg, i.c.v.            --                             Fentanyl (60 µg/kg)                    Rat (SD)                                   ↑ respiratory frequency; ↑\             [@ref-36]
  blocker                                                                                                                                                                                        inspiratory time                        

  Alpha 2-\               SK&F 86466               1 and 5 mg/kg, i.v.          α ~2~-adrenoceptor             Dermorphin (30 or 100\                 Rat (SD)                                   ↑ relative ventilator minute\           [@ref-37]
  adrenoceptor\                                                                                                pmol)                                                                             volume; ↑respiratory rate; ↓ CO ~2~\    
  antagonist                                                                                                                                                                                     production                              

  AChE inhibitor          Donepezil                0.4 mg/kg, i.v.              Acetylcholinesterase           Morphine (2 mg/kg, i.v.)               Rabbit                                     ↑ Respiratory rate; ↑ respiratory\      [@ref-38]
                                                                                                                                                                                                 amplitude; ↑ minute phrenic\            
                                                                                                                                                                                                 activity; ↓ phrenic nerve apnea\        
                                                                                                                                                                                                 threshold PaCO ~2~                      

  Donepezil               0.4 mg/kg, i.v.          Acetylcholinesterase         Buprenorphine (0.02\           Rabbit                                 ↑ Respiratory rate; ↑ respiratory\         [@ref-39]                               
                                                                                mg/kg, i.v.)                                                          amplitude; ↑ minute phrenic\                                                       
                                                                                                                                                      activity                                                                           

  RA ~6~                  1 mg i.v., 2 mg s.c.     Acetylcholinesterase         Morphine (8 mg, i.v.)          Rabbit                                 ↑ Respiratory rate; ↓ PaCO ~2~             [@ref-40]                               

  RA ~7~                  1 or 2 mg, i.v.          Acetylcholinesterase         Morphine (8 mg, i.v.)          Rabbit                                 ↑ Respiratory rate; ↓ PaCO ~2~             [@ref-40]                               

  RA ~15~                 0.25 or 0.5 mg, i.v.     Acetylcholinesterase         Morphine (8 mg, i.v.)          Rabbit                                 ↑ Respiratory rate; ↓ PaCO ~2~             [@ref-40]                               

  Physostigmine           0.05 or 0.1 mg, i.v.     Acetylcholinesterase         Morphine (8 mg, i.v.)          Rabbit                                 ↓ PaCO ~2~                                 [@ref-40]                               

  Others                  *4-aminopyridine*        0.25 mg/kg, i.v.             Potassium channel\             Fentanyl (0.6--0.9 mg)                 Human                                      ↑ Respiratory rate; ↑ tidal volume;\    [@ref-41]
                                                                                blocker                                                                                                          ↑ maximum occlusion pressure;\          
                                                                                                                                                                                                 ↓ PaCO ~2~                              

  *Glycyl-L-*\            1--100 nmol, i.c.v.      Brainstem neurons            Morphine (40 nmol, i.c.v.)     Rat (SD)                               Inhibited hypercapnia (PaCO ~2~),\         [@ref-42]                               
  *glutamine*                                                                                                                                         hypoxia (PaO ~2~), and acidosis\                                                   
                                                                                                                                                      (blood pH) evoked by morphine                                                      

  *Thyrotropin-*\         2--5 mg/kg, i.v., i.t.   --                           Morphine (5--15 mg/kg,\        Rat (SD)                               ↑ Respiratory rate; ↑ tidal volume;\       [@ref-43]                               
  *releasing*\                                                                  i.v.)                                                                 ↓ PaCO ~2~                                                                         
  *hormone*                                                                                                                                                                                                                              

  *Taltirelin*            1--2 mg/kg, i.v., i.t.   --                           Morphine (5--15 mg/kg,\        Rat (SD)                               ↑ Respiratory rate; ↑ tidal volume;\       [@ref-43]                               
                                                                                i.v.)                                                                 ↓ PaCO ~2~; ↑ PaO ~2~                                                              
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

5-HT, 5-hydroxytryptamine; α4β2, alpha-4 beta-2 nicotinic receptor; AMPA, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; D ~1~, dopamine receptor D1; GIRK, G-protein-gated inwardly rectifying potassium; i.c.v., intracerebroventricular; i.m., intramuscular; i.p., intraperitoneal; i.t., intrathecal; i.v., intravenous; KM, Kun Ming; NMDA, N-methyl-D-aspartate; PaCO ~2~, partial pressure of carbon dioxide; PaO ~2~, partial pressure of oxygen; PDE4, phosphodiesterase 4; PKA, protein kinase A; SaO ~2~, oxygen saturation; s.c., subcutaneous; SD, Sprague Dawley; WH, Wistar Han.

Ampakines are positive allosteric modulators of the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor, which has a key role in the maintenance of respiratory drive in the pre-Botzinger complex and other central nervous system sites ^[@ref-2]^. In both animals and humans, ampakines stimulate respiratory drive, particularly under hypoventilatory conditions ^[@ref-2]^. CX717 is one of two ampakines tested in humans that have been shown to partially reverse alfentanil-induced respiratory depression ^[@ref-7]^. The other, CX1739, has been assessed in a phase 2 clinical trial for its capacity to antagonize remifentanil-induced respiratory depression; however, the results are not published as yet (ClinicalTrials.gov; Identifier: NCT02735629). Apart from evoking respiratory stimulation, ampakines augment morphine-induced antinociception in rats, showing the utility of combining an opioid with an ampakine to produce potent pain relief but with a superior respiratory safety profile compared with an equi-analgesic dose of morphine alone ^[@ref-8]^. More recently, single intravenous (i.v.) bolus doses of the ampakine LCX001 prevented and reversed fentanyl-induced respiratory depression in rats by strengthening respiratory frequency and minute ventilation whilst maintaining opioid analgesia ^[@ref-9]^. Encouragingly, i.v. LCX001 also produced dose-dependent antinociception in rats ^[@ref-9]^.

In other work, i.v. administration of either nicotine or the α4β2 nicotinic acetylcholine receptor agonist A85380, but not the α7 nicotinic acetylcholine receptor agonist PNU282987, rapidly reversed fentanyl-induced respiratory depression and apnea in rats in a manner comparable to i.v. dosing with the opioid receptor antagonist naloxone ^[@ref-10]^. Additionally, i.v. A85380 potentiated fentanyl-induced antinociception in rats consistent with earlier work showing that agonists of the nicotinic α4β2 receptor evoke antinociception ^[@ref-10]^. Furthermore, A85380 had a modest effect on fentanyl-induced sedation in rats ^[@ref-10]^. Remifentanil is a highly potent respiratory depressant that is particularly difficult to reverse by either a low dose of naloxone or an ampakine in a recent clinical trial ^[@ref-11]^. Thus, the finding that i.v. remifentanil-induced apnea was markedly reduced by co-administration of i.v. A85380 is of particular interest ^[@ref-10]^. The respiratory protective effects of A85380 appear to be underpinned by the fact that the nicotinic acetylcholine receptor subunits α4 and β2 are expressed by the medullary respiratory network and activation of α4β2 receptors increases respiratory rhythm ^[@ref-10]^. Additionally, α4β2 receptors are present in the carotid bodies and so they may also potentially contribute to the respiratory stimulant effects of A85380 ^[@ref-10]^. The water solubility of A85380 like naloxone, together with its much longer half-life at approximately 7 hours compared with 15--30 minutes for naloxone ^[@ref-10]^, support the progression of this compound towards clinical trials.

Doxapram is widely used in veterinary practice to reverse opioid-induced respiratory depression. In goats, i.v. doxapram reduced etorphine-induced respiratory depression by rapid reversal of all respiratory parameters except tidal volume ^[@ref-12]^. In adult humans, doxapram is used to reverse respiratory depression post-anesthesia by direct input on brainstem centers with differential effects on the pre-Botzinger complex and the downstream motor output (XII) ^[@ref-13]^. In preterm infants with apnea of prematurity insensitive to caffeine treatment, doxapram infusion significantly reduced apnea episodes primarily by its effect on respiratory drive rather than on respiratory muscle ^[@ref-14]^. Interestingly, the molecular mechanism underpinning the respiratory stimulant effects of doxapram is restricted to the positive enantiomer and involves inhibition of human TWIK-related acid-sensitive K ^+^-channels (TASK), in particular TASK-1 and TASK-3 channels that are expressed in the carotid body ^[@ref-15],\ [@ref-16]^.

Recent work in anaesthetized rabbits has shed new light on the mechanism by which 5-HT receptor agonists stimulate respiratory parameters, including minute ventilation, respiratory rate, and tidal volume ^[@ref-17]^. Specifically, bilateral microinjection of 5-HT caused excitatory activity of the pre-Botzinger complex via a mechanism mediated by 5-HT ~1A~ and 5-HT ~3~ receptors ^[@ref-17]^.

Other pharmacological classes assessed for their ability to blunt opioid-induced respiratory depression include PKA inhibitors, GIRK inhibitors, and thyrotropin-releasing hormone (TRH) analogs. Specifically, fentanyl-induced respiratory depression was attenuated in unrestrained rats by intracerebroventricular (i.c.v.) bolus doses of the PKA inhibitor H89 ^[@ref-36]^ and by the GIRK inhibitor tertiapin-Q ^[@ref-36]^. In anaesthetized rats, TRH and its long-acting analog, taltirelin, evoked a marked increase in respiratory rate, tidal volume, and blood oxygenation after i.v. co-administration with morphine ^[@ref-43]^.

In a proof-of-concept clinical study in healthy human subjects, i.v. infusion of the NMDA receptor antagonist esketamine at a subanesthetic dose dose-dependently reversed respiratory depression induced by i.v. remifentanil ^[@ref-35]^. This was underpinned by a stimulatory effect on ventilatory CO ~2~ chemosensitivity that was otherwise reduced by remifentanil alone ^[@ref-35]^. The esketamine effect had a rapid onset of action and it was driven by plasma pharmacokinetics ^[@ref-35]^. By contrast, esketamine had little or no effect on resting ventilation. Of concern, however, is that two of 14 subjects withdrew from the study owing to the psychotomimetic side-effects of esketamine ^[@ref-35]^.

Conclusions
===========

The US opioid epidemic has focused attention on the discovery of respiratory stimulants to reverse opioid-induced respiratory depression whilst sparing opioid analgesia. Although progress has been made, most studies have been confined to the preclinical setting. Very few molecules have entered clinical development, and there are currently no ongoing clinical trials of respiratory stimulants registered on ClinicalTrials.gov (accessed 5 December 2019). Hence, considerable work remains before respiratory stimulant molecules with promising preclinical and/or human data become available for use in clinical practice.
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